Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
SA-237 for neuromyelitis optica and neuromyelitis optica spectrum disorders	Satralizumab (SA237; RG6168)	Neuromyelitis optica , Neuromyelitis optica spectrum disorders	Neurology , Ophthalmology	2017	View \| Download
Ruxolitinib for treating chronic graft versus host disease after allogeneic stem cell transplant in paediatric patients	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2023	View \| Download
Ruxolitinib for grades II-IV treatment-naïve or steroid-refractory acute graft versus host disease	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2023	View \| Download
Ruxolitinib for chronic graft versus host disease (cGvHD)	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2019	View \| Download
Ruxolitinib for acute graft versus host disease (aGvHD)	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Graft versus host disease (GvHD)	Immunology	2019	View \| Download
Ruxolitinib cream for vitiligo	Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Vitiligo	Dermatology	2021	View \| Download
Rucaparib with nivolumab for the maintenance treatment of newly diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Breast cancer	Breast Cancer	2022	View \| Download
Rucaparib maintenance therapy for ovarian, fallopian tube or primary peritoneal cancer after frontline platinum-based chemotherapy	Rucaparib (Rubraca; PF-1367338)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2022	View \| Download
Rucaparib for metastatic castration-resistant prostate cancer associated with homologous recombination deficiency	Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Rucaparib (Rubraca) for platinum-sensitive, high-grade serous or endometrioid epithelial ovarian cancer, primary peritoneal or fallopian tube cancer	Rucaparib (Rubraca; PF-1367338)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2018	View \| Download